Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
 EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Volume 11, Number 6, June 2005

Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

John M. Stelling,*† Karin Travers,* Ronald N. Jones,‡§ Philip J. Turner,¶ Thomas F. O'Brien,*† and Stuart B. Levy*§
*Alliance for the Prudent Use of Antibiotics, Boston, Massachusetts, USA; †Brigham and Women's Hospital, Boston, Massachusetts, USA; ‡The Jones Group, North Liberty, Iowa, USA; §Tufts University, Boston, Massachusetts, USA; and ¶AstraZeneca, Macclesfield, Cheshire, United Kingdom

 
 
Figure 3.
  Back to article
 

Figure 3. SENTRY results for antimicrobial agents tested in common with MYSTIC. Annual nonsusceptibility rates of Escherichia coli, 1997–2001. p<0.05. CAZ, ceftazidime; TZP, piperacillin/tazobactam; GEN, gentamicin; CIP, ciprofloxacin; TOB, tobramycin; FEP, cefepime.

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed May 18, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention